BioNano Genomics Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.76. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SPXL | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.92 | $296.39 |
52-Week Low | $1.06 | $170.20 |
Enterprise Value | $16.26M | — |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
SPXL trades at $295.71, down 0.16% with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength while RSI levels suggest potential overbought conditions. Recent news highlights S&P 500 reaching record highs with JPMorgan raising its 2026 target to 8,000, citing AI-driven earnings strength and corporate performance.
The leveraged ETF benefits from strong market momentum but faces valuation concerns with the S&P 500 at historically high Shiller P/E ratios. Key risks include market volatility ahead of inflation reports and potential profit-taking near resistance levels. The AI investment theme provides growth catalysts, though elevated valuations warrant caution for new positions.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →